Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More
SUN PHARMA | STERLING BIOTECH | SUN PHARMA/ STERLING BIOTECH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 21.8 | -0.4 | - | View Chart |
P/BV | x | 2.5 | 0.0 | 17,892.4% | View Chart |
Dividend Yield | % | 0.6 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUN PHARMA Mar-19 |
STERLING BIOTECH Dec-13 |
SUN PHARMA/ STERLING BIOTECH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 679 | 11 | 6,464.8% | |
Low | Rs | 375 | 3 | 11,041.2% | |
Sales per share (Unadj.) | Rs | 121.1 | 26.8 | 451.9% | |
Earnings per share (Unadj.) | Rs | 13.4 | -15.0 | -89.4% | |
Cash flow per share (Unadj.) | Rs | 20.7 | -5.5 | -378.6% | |
Dividends per share (Unadj.) | Rs | 2.75 | 0 | - | |
Dividend yield (eoy) | % | 0.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 172.6 | 54.9 | 314.5% | |
Shares outstanding (eoy) | m | 2,399.26 | 267.87 | 895.7% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.4 | 0.3 | 1,678.2% | |
Avg P/E ratio | x | 39.4 | -0.5 | -8,480.3% | |
P/CF ratio (eoy) | x | 25.5 | -1.3 | -2,003.0% | |
Price / Book Value ratio | x | 3.1 | 0.1 | 2,411.7% | |
Dividend payout | % | 20.6 | 0 | - | |
Avg Mkt Cap | Rs m | 1,264,650 | 1,862 | 67,929.9% | |
No. of employees | `000 | 17.5 | 1.4 | 1,292.5% | |
Total wages/salary | Rs m | 59,671 | 547 | 10,912.7% | |
Avg. sales/employee | Rs Th | 16,608.1 | 5,303.3 | 313.2% | |
Avg. wages/employee | Rs Th | 3,409.6 | 403.8 | 844.3% | |
Avg. net profit/employee | Rs Th | 1,833.8 | -2,959.0 | -62.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 290,659 | 7,181 | 4,047.8% | |
Other income | Rs m | 10,255 | 43 | 24,072.5% | |
Total revenues | Rs m | 300,914 | 7,223 | 4,165.9% | |
Gross profit | Rs m | 63,076 | 947 | 6,661.3% | |
Depreciation | Rs m | 17,533 | 2,543 | 689.4% | |
Interest | Rs m | 5,553 | 4,377 | 126.9% | |
Profit before tax | Rs m | 50,246 | -5,931 | -847.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -12,144 | 0 | - | |
Tax | Rs m | 6,009 | -1,924 | -312.3% | |
Profit after tax | Rs m | 32,093 | -4,007 | -801.0% | |
Gross profit margin | % | 21.7 | 13.2 | 164.6% | |
Effective tax rate | % | 12.0 | 32.4 | 36.9% | |
Net profit margin | % | 11.0 | -55.8 | -19.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 310,692 | 14,335 | 2,167.4% | |
Current liabilities | Rs m | 173,396 | 49,809 | 348.1% | |
Net working cap to sales | % | 47.2 | -494.0 | -9.6% | |
Current ratio | x | 1.8 | 0.3 | 622.6% | |
Inventory Days | Days | 99 | 403 | 24.6% | |
Debtors Days | Days | 112 | 171 | 65.4% | |
Net fixed assets | Rs m | 232,477 | 55,432 | 419.4% | |
Share capital | Rs m | 2,399 | 268 | 895.6% | |
"Free" reserves | Rs m | 411,691 | 13,935 | 2,954.3% | |
Net worth | Rs m | 414,091 | 14,701 | 2,816.7% | |
Long term debt | Rs m | 15,226 | 9,478 | 160.6% | |
Total assets | Rs m | 646,938 | 73,988 | 874.4% | |
Interest coverage | x | 10.0 | -0.4 | -2,831.1% | |
Debt to equity ratio | x | 0 | 0.6 | 5.7% | |
Sales to assets ratio | x | 0.4 | 0.1 | 462.9% | |
Return on assets | % | 5.8 | 0.5 | 1,161.7% | |
Return on equity | % | 7.8 | -27.3 | -28.4% | |
Return on capital | % | 10.2 | -6.4 | -158.2% | |
Exports to sales | % | 0 | 25.9 | 0.0% | |
Imports to sales | % | 0 | 0.2 | 0.0% | |
Exports (fob) | Rs m | NA | 1,860 | 0.0% | |
Imports (cif) | Rs m | NA | 12 | 0.0% | |
Fx inflow | Rs m | 66,025 | 1,860 | 3,550.1% | |
Fx outflow | Rs m | 38,610 | 25 | 155,123.3% | |
Net fx | Rs m | 27,415 | 1,835 | 1,494.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 21,965 | 1,719 | 1,278.0% | |
From Investments | Rs m | -6,813 | -3,148 | 216.4% | |
From Financial Activity | Rs m | -27,305 | 1,426 | -1,914.8% | |
Net Cashflow | Rs m | -8,442 | -3 | 248,279.4% |
Indian Promoters | % | 63.7 | 33.9 | 187.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 5.1 | 0.0 | - | |
FIIs | % | 23.0 | 9.9 | 232.3% | |
ADR/GDR | % | 0.0 | 16.9 | - | |
Free float | % | 8.3 | 39.3 | 21.1% | |
Shareholders | 133,026 | 21,482 | 619.2% | ||
Pledged promoter(s) holding | % | 0.5 | 55.9 | 0.9% |
Compare SUN PHARMA With: ALEMBIC PHARMA STRIDES PHARMA SCIENCE FDC LTD. ASTRAZENECA PHARMA BIOCON
Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
| |
Stock markets remained rangebound this week too. Macroeconomic news globally and domestically remained the focus of the week.
For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
More Views on NewsWhat to do after every trade.
A high probability trade that worked to perfection for my subscribers.
This corner of the market could provide more returns than blue chips in 2020.
Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
2019 will be remembered as the year of great money-making IPOs...
More